CN101543514A - 预防或治疗阴道炎的复合乳酸菌洁阴护理液及工艺 - Google Patents
预防或治疗阴道炎的复合乳酸菌洁阴护理液及工艺 Download PDFInfo
- Publication number
- CN101543514A CN101543514A CN200910011471A CN200910011471A CN101543514A CN 101543514 A CN101543514 A CN 101543514A CN 200910011471 A CN200910011471 A CN 200910011471A CN 200910011471 A CN200910011471 A CN 200910011471A CN 101543514 A CN101543514 A CN 101543514A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus
- percent
- vagina
- weight percent
- compound lactobacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000186660 Lactobacillus Species 0.000 title claims abstract description 60
- 229940039696 lactobacillus Drugs 0.000 title claims abstract description 58
- 150000001875 compounds Chemical class 0.000 title claims abstract description 26
- 238000005516 engineering process Methods 0.000 title claims abstract description 16
- 210000001215 vagina Anatomy 0.000 title abstract description 35
- 238000004140 cleaning Methods 0.000 title abstract description 7
- 206010046914 Vaginal infection Diseases 0.000 title abstract description 6
- 201000008100 Vaginitis Diseases 0.000 title abstract description 4
- 239000006210 lotion Substances 0.000 title abstract 2
- 239000007788 liquid Substances 0.000 claims abstract description 36
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 28
- 238000000855 fermentation Methods 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000004310 lactic acid Substances 0.000 claims abstract description 14
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 10
- 239000008103 glucose Substances 0.000 claims abstract description 10
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 9
- 229940041514 candida albicans extract Drugs 0.000 claims abstract description 9
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 claims abstract description 9
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims abstract description 9
- 239000001963 growth medium Substances 0.000 claims abstract description 9
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000012138 yeast extract Substances 0.000 claims abstract description 9
- 241000251468 Actinopterygii Species 0.000 claims abstract description 6
- 239000001888 Peptone Substances 0.000 claims abstract description 5
- 108010080698 Peptones Proteins 0.000 claims abstract description 5
- 235000019319 peptone Nutrition 0.000 claims abstract description 5
- 230000003750 conditioning effect Effects 0.000 claims description 23
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 12
- 230000004151 fermentation Effects 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 10
- 230000001580 bacterial effect Effects 0.000 claims description 9
- 239000008367 deionised water Substances 0.000 claims description 9
- 229910021641 deionized water Inorganic materials 0.000 claims description 9
- 239000004386 Erythritol Substances 0.000 claims description 8
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 8
- 229940009714 erythritol Drugs 0.000 claims description 8
- 235000019414 erythritol Nutrition 0.000 claims description 8
- 239000001393 triammonium citrate Substances 0.000 claims description 8
- 235000011046 triammonium citrate Nutrition 0.000 claims description 8
- 208000004926 Bacterial Vaginosis Diseases 0.000 claims description 7
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 6
- 239000001632 sodium acetate Substances 0.000 claims description 6
- 235000017281 sodium acetate Nutrition 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 abstract description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract description 6
- 239000002207 metabolite Substances 0.000 abstract description 6
- 208000036649 Dysbacteriosis Diseases 0.000 abstract description 5
- 208000027244 Dysbiosis Diseases 0.000 abstract description 5
- 230000007140 dysbiosis Effects 0.000 abstract description 5
- 108010062877 Bacteriocins Proteins 0.000 abstract description 2
- 108090000790 Enzymes Proteins 0.000 abstract description 2
- 102000004190 Enzymes Human genes 0.000 abstract description 2
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 2
- 229930195729 fatty acid Natural products 0.000 abstract description 2
- 239000000194 fatty acid Substances 0.000 abstract description 2
- 150000004665 fatty acids Chemical class 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 229920001184 polypeptide Polymers 0.000 abstract description 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 150000002978 peroxides Chemical class 0.000 abstract 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 abstract 1
- 235000019477 peppermint oil Nutrition 0.000 abstract 1
- 230000001902 propagating effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000036541 health Effects 0.000 description 6
- 230000002147 killing effect Effects 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 210000003756 cervix mucus Anatomy 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 238000012856 packing Methods 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 241000222122 Candida albicans Species 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 230000000721 bacterilogical effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000002085 irritant Substances 0.000 description 3
- 231100000021 irritant Toxicity 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010007134 Candida infections Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 201000003984 candidiasis Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 229940017800 lactobacillus casei Drugs 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000207202 Gardnerella Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000191992 Peptostreptococcus Species 0.000 description 1
- 208000008350 Pruritus Vulvae Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 1
- 206010047799 Vulvovaginitis trichomonal Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000002573 colposcopy Methods 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 235000020995 raw meat Nutrition 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
预防或治疗细菌性阴道炎的复合乳酸菌洁阴护理液及工艺,将德氏乳杆菌菌株种子液接入含有重量1-3%葡萄糖、0.5-1.5%大豆蛋白胨、0.5-1%酵母浸膏、0.5-1%鱼蛋白胨、0.3-0.5%柠檬酸三铵的培养基中,经36-39℃厌氧发酵后,按重量取离心分离液20-40%,还可取赤藓糖醇1-3%、乳酸1-3%、过氧化氢1-3%、冰片0.2-0.5%、薄荷油1-3%,其余为去离子水,充分混合。利用乳杆菌代谢产物如乳酸、醋酸、过氧化氢、细菌素及其他挥发性脂肪酸、有用的酶、多肽等活性物质调节阴道菌群失调,有效抑制外袭菌和过盛繁殖的阴道菌群中的少数种群,恢复其自然的抵抗外来菌侵扰的能力,促进其本身的生物自净作用来预防和治疗细菌性阴道炎。
Description
技术领域:
本发明涉及一种预防或治疗阴道炎的复合乳酸菌洁阴护理液剂,种用于妇女阴道保健及调整阴道菌群失调的阴道微生态调节剂(消毒剂),并涉及制备这种制剂的工艺。
背景技术:
健康妇女,阴道由于解剖组织的特点对病原体的侵入有自然防御功能。如阴道口的闭合,阴道前后壁紧贴,阴道上皮细胞在雌激素的影响下的增生,和表层细胞角化,阴道pH值保持在pH4-5,使适应碱性的病原体的繁殖受到抑制,而宫颈管粘液呈碱性,使适应酸性环境的病原体的繁殖受到抑制等,当阴道的自然防御功能受到破坏时,病原体易于侵入,导致发生阴道感染性疾病。幼女及绝经后妇女由于阴道上皮非常薄更易受到感染。寄生于健康妇女阴道中的细菌包括革兰氏阳性需氧菌,如乳酸杆菌、棒状杆菌、非溶血性链球菌、肠球菌、表皮葡萄糖球菌,革兰氏阴性需氧菌有大肠杆菌、加德纳菌。厌氧菌包括梭状芽胞杆菌、消化链球菌、类杆菌及梭形杆菌等,此外尚有Mobiluncns菌、支原体及念珠菌等。在这些正常阴道菌群中,以乳酸杆菌占优势,阴道乳酸杆菌对维持阴道正常菌群起着关键作用。阴道上皮的糖原经乳酸杆菌的作用分解成乳酸,使阴道局部呈弱酸环境,抑制其他寄生菌过度生长。此外部分乳酸杆菌尚能合成过氧化氢,这些过氧化氢阳性乳酸杆菌通过与其他氧化物联合作用可抑制其他细菌。另一方面乳酸杆菌造成的酸性环境又有利于减少细胞表面负电荷和去除覆盖于受体表面的糖基,暴露受体而有助于细菌粘附。因此乳酸杆菌是通过正反两方面调节正常阴道的菌群。但正如前述,当应用某些药物如广谱抗菌素、抗癌药物及免疫抑制剂,或受到某些感染如淋病、梅毒、艾滋病,或性激素等影响,都会导致阴道生态系统的平衡破坏。从微生态学的角度出发,通过生态制剂调整疗法,扶正和调节阴道内的正常菌群的组成和比例,恢复其自然的抵抗外来菌侵扰的能力,促进其本身的生物自净作用是治疗此类疾病的一种必然趋势。本发明在已调查大量健康妇女和患病妇女阴道菌群变化以及与妇女阴道保健的关系的基础上、开发出一种用于妇女阴道保健及调整阴道菌群失调的阴道微生态调节剂(消毒剂)
目前国内只有一种乳杆菌活菌阴道制剂应用于临床,对治疗各种阴道菌群失调性阴道炎、阴道霉菌感染及阴道滴虫病,均有较好的疗效,而且复发率低,无抗生素固有的耐药性、引起菌群失调及毒性反应等副作用。但作为活菌制剂本身存在许多缺点,如细菌存活期短,难于长时间保存,作为固体胶囊制剂,把本来应发挥自用的乳杆菌代谢产物如乳酸、醋酸、过氧化氢、细菌素及其他挥发性脂肪酸、一些有用的酶、多肽等活性物质全部扔掉。缺少乳杆菌代谢产物的微生态制剂是不完善的。
发明内容:
本发明的目的就是为了解决已有技术中实用,活菌制剂细菌存活期短,难于长时间保存,固体胶囊制剂把本来应发挥自用的乳杆菌代谢产物全部扔掉的许多缺点,提供一种通过生态制剂调整疗法,扶正和调节阴道内的正常菌群的组成和比例,恢复其自然的抵抗外来菌侵扰的能力,促进其本身的生物自净作用的阴道保健或预防细菌炎的复合乳酸菌洁阴护理液及工艺。
本发明的阴道保健或预防细菌炎的复合乳酸菌洁阴护理液,含有德氏乳杆菌乳酸亚种DM8909(Lactobacillus debrueckii subsp.lactis)(本菌种由中科院微生物研究所鉴定)发酵离心液20-40%;赤藓糖醇1-3%;乳酸1-3%;过氧化氢1-3%;冰片0.2-0.5%;薄荷油1-3%;其余为去离子水。充分混合后分装。
本发明涉及对德氏乳杆菌的微生物学实验、微生态学实验及生产工艺研究实验。微生物实验包括菌种分离、鉴定、生物特性、代谢产物、耐药性、代谢物、H202产生及质粒检测等。生态效应试验包括正常值调查、粘附、定植、生物拮抗、模型试验、安全试验、稳定试验和刺激试验等。生产工艺研究包括种子、发酵和制剂产品稳定性及工艺稳定性等方面的研究。基础研究还包括作用机制的研究。
本发明涉及的的德氏乳杆菌制备工艺如下:德氏乳杆菌上清液的制备:将德氏乳杆菌菌株种子液接入已经灭菌后的含有重量1-3%葡萄糖、0.5-1.5%大豆蛋白胨、0.5-1%酵母浸膏、0.2-0.5%乙酸钠、0.2-0.5%柠檬酸三铵的培养基中,经36℃-39℃厌氧发酵24-48小时后,离心分离,获得上清液,即发酵离心液。还可以加入0.2-0.5%乙酸钠。
本发明涉及的一种用于调整菌群预防或治疗细菌性阴道炎的复合乳酸菌洁阴护理液制备工艺:将德氏乳杆菌菌株种子液接入已经灭菌后的含有重量1-3%葡萄糖、0.5-1.5%大豆蛋白胨、0.5-1%酵母浸膏、0.5-1%鱼蛋白胨、0.2-0.5%柠檬酸三铵的培养基中,经36-39℃厌氧发酵后,离心分离获得离心上清液;将前面所述离心上清液按重量配比20-40%,赤藓糖醇1-3%,乳酸1-3%,过氧化氢1-3%,冰片0.2-0.5%,薄荷油1-3%,其余为去离子水进行混合。
其中,德氏乳杆菌制备的最佳过程如下:
德氏乳杆菌上清液的制备:将德氏乳杆菌菌株种子液接入已经灭菌后的含有重量2%葡萄糖、1%大豆蛋白胨、0.5%酵母浸膏、0.2%乙酸钠、0.2%柠檬酸三铵的培养基中,经37℃厌氧发酵48小时后,离心分离,获得上清液。
本发明相关研究如下:
(1)本复合乳酸菌洁阴护理液的微生物杀灭试验
依据《消毒与灭菌效果的评价方法与标准》(GB15981-19950,参照《消毒技术规范》。检验本复合乳酸菌洁阴护理液对大肠埃希菌(ATCC25922)、金黄色葡萄球菌(ATCC25923)、白色念珠菌(ATCC10231)、德氏乳杆菌(DM8909)、干酪乳杆菌(DM8121)杀灭效果。结果表明,本复合乳酸菌洁阴护理液对大肠埃希菌、金黄色葡萄球菌、白色念珠菌的杀灭率大于99.9%,对德氏乳杆菌杀灭率为54.4%、对干酪乳杆菌杀灭率为67.4%。
在37℃90天保藏后,对大肠杆菌的杀灭率大于99.9%。
(2)皮肤刺激试验
依据《消毒技术规范》第三版第一分册3.6皮肤刺激试验方法进行试验,结果表明,本复合乳酸菌洁阴护理液对受试动物大白兔皮肤刺激试验按刺激轻度分级属轻刺激性。
(3)阴道黏膜刺激试验
依据《消毒技术规范》第三版第一分册刺激试验方法进行试验结果表明,本复合乳酸菌洁阴护理液对受试动物大白鼠阴道黏膜刺激试验按皮肤刺激强度评分标准和分级标准判定为无刺激性。
(4)对细菌性阴道炎的临床疗效观察
对患有细菌性阴道炎的24例患者采用复合乳酸菌洁阴护理液进行治疗,每晚睡前取本品10ml加5~10倍量温水稀释后清洗阴道或外阴。炎症传染期,可将本品加量到20ml清洗,一个疗程10天,用药后3天返回门诊,了解病情变化情况,停药后3d复查临床症状、实验室检查等,与自身对照比较疗效及安全性。对照组12例患者在冲洗外阴及阴道后,置阴道后穹窿部甲硝唑栓一枚,每晚一次,同时口服甲硝唑片0.2g Tid,共7~10天。治疗效果如下表1。对照组及治疗组治疗前后均出现好转现象,两组之间有效率比较,无显著差异(P>0.05)。治疗前后阴道分泌物情况见表2。
表1对24例BV患者治疗结果(例数)
表2使用本制剂对BV患者阴道分泌物的治疗效果比较:
具体实施方式:
实施例1将德氏乳杆菌菌株种子液接入已经灭菌后的含有重量比为3%葡萄糖、1%大豆蛋白胨、0.8酵母浸膏、0.8%鱼蛋白胨、0.4%柠檬酸三铵的培养基中,经36-39℃厌氧发酵后,离心分离,获得离心上清液,即发酵离心液。取400g发酵离心液,用去离子水加至1000ml,形成复合乳酸菌洁阴护理液。
实施例2德氏乳杆菌发酵离心液300g;赤藓糖醇20g;乳酸20g;过氧化氢30g;冰片3g;薄荷油2g;去离子水加至670ml。充分混合后分装,制得复合乳酸菌洁阴护理液。其中德氏乳杆菌发酵理性也制备方法如下:将德氏乳杆菌菌株种子液按重量3%接种量接入已经灭菌后的含有重量3%葡萄糖、0.5%大豆蛋白胨,0.5%鱼蛋白胨、0.8%酵母浸膏、0.35%柠檬酸三铵培养基中,经37℃厌氧发酵后,离心分离出菌体获得发酵离心液。
实施例3一种本发明的阴道保健或预防细菌炎的复合乳酸菌洁阴护理液及制备工艺如下:
将德氏乳杆菌菌株种子液接入已经灭菌后的含有重量2%葡萄糖、1%大豆蛋白胨、0.5%酵母浸膏、0.2%乙酸钠、0.2%柠檬酸三铵的培养基中,经37℃厌氧发酵48小时后,离心分离,获得的上清液即为发酵离心液。取发酵离心液400g;赤藓糖醇20g;乳酸20g;甘油50g;冰片2g;薄荷油3g;去离子水加至1000ml。充分混合后分装。对患有细菌性阴道炎的患者采用实施例2方法制得的复合乳酸菌洁阴护理液进行治疗,每晚睡前取本品10ml加5~10倍量温水稀释后清洗阴道或外阴。炎症传染期,可将本品加量到20ml清洗,一个疗程10天。
实施例4按重量比取实施例1的发酵离心液250g;赤藓糖醇10g;乳酸10g;甘油50g;冰片1g;薄荷油1.2g;;去离子水加至1000ml。充分混合后分装,制得复合乳酸菌洁阴护理液。
患者李某某,42岁,患有细菌性阴道炎。阴道分泌物呈灰色均质,粘度低,粘附于阴道壁偶成泡沫状,鱼腥样臭味;阴道pH值5.0~5.5;阴道分泌物湿涂片检出线索细胞。该患者采用实施例2方法制得的复合乳酸菌洁阴护理液进行治疗,每晚睡前取本品10ml加5~10倍量温水稀释后清洗阴道或外阴。使用一个疗程10天后,患者阴道骚痒、白带多症状消失;阴道线索细胞转为阴性,pH<4.5,10%KOH实验阴性。患者痊愈。
实施例5按重量比取实施例1的发酵离心液350g;赤藓糖醇30g;乳酸26g;甘油20g;冰片1.6g;薄荷油3.2g;;去离子水加至1000ml。充分混合后分装,制得复合乳酸菌洁阴护理液。患者张某某,37岁,患有霉菌性阴道炎,主要症状外阴瘙痒并伴有灼痛,白带增多,可见阴道粘膜上有一层白色粘稠或豆腐渣样分泌物覆盖,粘膜充血红肿,表浅溃疡。阴道镜检发现霉菌。该患者采用实施例2方法制得的复合乳酸菌洁阴护理液进行治疗,每晚睡前取本品10ml加5~10倍量温水稀释后清洗阴道或外阴。使用2个疗程20天后,患者阴道骚痒、白带多症状消失;阴道分泌物镜检未见念珠菌孢子和菌丝。患者痊愈。
Claims (5)
1、一种用于调整菌群预防或治疗细菌性阴道炎的复合乳酸菌洁阴护理液,其特征在于:按重量比含有德氏乳杆菌乳酸亚种发酵离心液20-40%。
2、如权利要求1所说的复合乳酸菌洁阴护理液,其特征在于:按重量比还含有赤藓糖醇1-3%;乳酸1-3%;过氧化氢1-3%;冰片0.2-0.5%;薄荷油1-3%;其余为去离子水。
3、一种用于调整菌群预防或治疗细菌性阴道炎的复合乳酸菌洁阴护理液制备工艺:将德氏乳杆菌菌株种子液接入已经灭菌后的含有重量1-3%葡萄糖、0.5-1.5%大豆蛋白胨、0.5-1%酵母浸膏、0.5-1%鱼蛋白胨、0.3-0.5%柠檬酸三铵的培养基中,经36-39℃厌氧发酵后,离心分离获得离心上清液;将前面所述离心上清液按重量配比20-40%,赤藓糖醇1-3%,乳酸1-3%,过氧化氢1-3%,冰片0.2-0.5%,薄荷油1-3%,其余为去离子水进行混合。
4、如权利要求3所说的复合乳酸菌洁阴护理液制备工艺,加入0.2-0.5%乙酸钠。
5、如权利要求3所说的复合乳酸菌洁阴护理液制备工艺,将德氏乳杆菌菌株种子液接入已经灭菌后的含有重量2%葡萄糖、1%大豆蛋白胨、0.5%酵母浸膏、0.2%乙酸钠、0.2%柠檬酸三铵的培养基中,经37℃厌氧发酵48小时。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910011471A CN101543514A (zh) | 2009-05-06 | 2009-05-06 | 预防或治疗阴道炎的复合乳酸菌洁阴护理液及工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910011471A CN101543514A (zh) | 2009-05-06 | 2009-05-06 | 预防或治疗阴道炎的复合乳酸菌洁阴护理液及工艺 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101543514A true CN101543514A (zh) | 2009-09-30 |
Family
ID=41191056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200910011471A Pending CN101543514A (zh) | 2009-05-06 | 2009-05-06 | 预防或治疗阴道炎的复合乳酸菌洁阴护理液及工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101543514A (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101797269A (zh) * | 2010-03-23 | 2010-08-11 | 杨霞 | 一种调节女性阴道微生态的生理平衡液 |
CN104644533A (zh) * | 2013-11-25 | 2015-05-27 | 云南海正生物科技有限公司 | 一种女性护理液的制作方法 |
CN106823013A (zh) * | 2016-12-31 | 2017-06-13 | 天津瑞特医疗保健用品开发有限公司 | 生物菌膜及其制备方法、保养方法和应用 |
CN108014287A (zh) * | 2018-02-02 | 2018-05-11 | 上海哈美实业发展有限公司 | 一种泡腾抑菌片及其制备方法 |
CN116083269A (zh) * | 2022-08-12 | 2023-05-09 | 深圳市盐田区人民医院 | 一种德氏乳杆菌印度亚种及其培养方法与应用 |
-
2009
- 2009-05-06 CN CN200910011471A patent/CN101543514A/zh active Pending
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101797269A (zh) * | 2010-03-23 | 2010-08-11 | 杨霞 | 一种调节女性阴道微生态的生理平衡液 |
CN104644533A (zh) * | 2013-11-25 | 2015-05-27 | 云南海正生物科技有限公司 | 一种女性护理液的制作方法 |
CN106823013A (zh) * | 2016-12-31 | 2017-06-13 | 天津瑞特医疗保健用品开发有限公司 | 生物菌膜及其制备方法、保养方法和应用 |
CN108014287A (zh) * | 2018-02-02 | 2018-05-11 | 上海哈美实业发展有限公司 | 一种泡腾抑菌片及其制备方法 |
CN116083269A (zh) * | 2022-08-12 | 2023-05-09 | 深圳市盐田区人民医院 | 一种德氏乳杆菌印度亚种及其培养方法与应用 |
CN116083269B (zh) * | 2022-08-12 | 2024-09-20 | 深圳市盐田区人民医院 | 一种德氏乳杆菌印度亚种及其培养方法与应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cundell | Microbial ecology of the human skin | |
CA2609754C (en) | Compositions of benzoic acid and saccharides for regulating and maintaining bacterial flora and acidity in the vagina | |
US8222020B2 (en) | Biologically pure strain of Lactobacillus fermentum, strain Ess-1 | |
US20090130236A1 (en) | Anti-microbial agent and anti-microbial composition | |
KR101720145B1 (ko) | 여성 질염 예방 및 개선 기능성 조성물 | |
TW201531560A (zh) | 一種捲曲乳桿菌(lactobacillus crispatus)及其應用 | |
CN109078069B (zh) | 阴道黏膜抗菌凝胶剂及其制备方法 | |
CN109985069B (zh) | 益生菌组合物及其用途 | |
CN101543514A (zh) | 预防或治疗阴道炎的复合乳酸菌洁阴护理液及工艺 | |
CN109402002A (zh) | 一种加氏乳杆菌及其在制备预防早产药物中的应用 | |
CN105663172A (zh) | 一种生态妇科外用药物组合物及其制备方法和应用 | |
CN105232526B (zh) | 含儿茶素的药物在制备抑菌药物中的用途 | |
CN103157095B (zh) | 芸豆植物凝集素在制备人用药物中的应用及其药物组合物 | |
EP3548045A1 (en) | Urogenital medical device formulation based on suitable biochemical compositions for the stabilization of the acidity and the redox state of the vaginal fluid | |
CN113278548B (zh) | 卷曲乳杆菌及在生产改善人体阴道环境的产品中的应用 | |
TWI412371B (zh) | 抑制陰道炎病原菌之乳酸桿菌及其用途 | |
KR20150075447A (ko) | 여성 자궁 질염 예방 및 개선 기능성 조성물 | |
WO2022255568A1 (ko) | 질염 예방 또는 치료용 조성물 | |
CN106047767A (zh) | 一种用于卫生巾、护垫的微生物菌粉添加剂及其制备方法 | |
CN102048729A (zh) | 一种治疗阴道炎的制剂 | |
CN110101655A (zh) | 一种修复宫颈及预防细菌性阴道炎的组合物 | |
CN113662998A (zh) | 一种用于治疗阴道炎和妇科炎症的药物组合物及制备方法 | |
KR102486025B1 (ko) | 생유산균을 포함하고 질염 개선에 도움을 주는 여성청결제용 조성물 | |
CN118726136B (zh) | 一株可调节生殖道微生态和修复生殖道黏膜屏障损伤的鼠李糖乳酪杆菌bb520及其应用 | |
CN111135157A (zh) | 3-苯乳酸及益生质的组合用于改善菌相的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090930 |